Bhairavi V. Tolani, Ph.D.
Affiliations: | 2013 | Molecular Biology | University of Southern California, Los Angeles, CA, United States |
Area:
Molecular Biology, Oncology, Virology BiologyGoogle:
"Bhairavi Tolani"Parents
Sign in to add mentor| Preet Chaudhary | grad student | 2013 | USC | |
| (Molecular strategies towards inhibition of KSHV-associated malignancies.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jiang L, Tolani B, Yeh CC, et al. (2019) Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma. Cancer Management and Research. 11: 8209-8218 |
| Tolani B, Hoang NT, Acevedo LA, et al. (2018) Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog. Oncotarget. 9: 14311-14323 |
| Tolani B, Acevedo LA, Hoang NT, et al. (2018) Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications. International Journal of Molecular Sciences. 19 |
| Leprieur EG, Tolani B, Li H, et al. (2017) Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer. Oncotarget. 8: 103744-103757 |
| Li H, Yue D, Jin JQ, et al. (2016) Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget |
| Gopalakrishnan R, Matta H, Tolani B, et al. (2016) Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 35: 1797-810 |
| Yue D, Li H, Che J, et al. (2015) EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. Plos One. 10: e0132134 |
| Tolani B, Matta H, Gopalakrishnan R, et al. (2014) NEMO is essential for Kaposi's sarcoma-associated herpesvirus-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death, and its N-terminal 251 residues are sufficient for this process. Journal of Virology. 88: 6345-54 |
| Tolani B, Gopalakrishnan R, Punj V, et al. (2014) Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 33: 2928-37 |
| Gopalakrishnan R, Matta H, Tolani B, et al. (2014) Immunomodulatory Drugs Are Efficacious Against Primary Effusion Lymphoma By Targeting IKZF1, IRF4 and MYC in a CRBN-Dependent Manner and Are Synergistic with BRD4 Inhibitors Blood. 124: 3109-3109 |